RBR-10chb63w尚未招募Unknown
Combined bleaching using in-office bleaching agents with pHs different: a randomized clinical trial
niversidade Ceuma0 个研究点开始时间: 2023年5月29日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18Y 至 0（—）
入选标准
- •Healthy volunteers; both genders; minimum age of 18 years and maximum without limit; non smokers; have vital teeth free of carious lesions; non-carious in the anterior region; free from periodontal disease; and the upper right canine should be A2 or darker in color compared to the Vita Classical scale; patients must sign the Informed Consent Form after explaining the details of the research
排除标准
- •Volunteers with previous tooth sensitivity; who never performed any type of dental bleaching; smokers, pregnant or breastfeeding women; in continuous use of medications such as analgesics or anti-inflammatories; who do not use prostheses; no restorations on the upper anterior teeth; are not using fixed orthodontic appliance; without any parafunction; no gingival recession; no endodontic treatment of anterior teeth, no severe dental discoloration (tetracycline staining or fluorosis) and visible cracks in teeth
研究者
相似试验
进行中（未招募）
不适用
A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis.Subjects with active sight-threatening, non-infectious intermediate-, anterior and intermediate-, posterior- or pan-uveitis.MedDRA version: 8.1Level: LLTClassification code 10046851Term: UveitisEUCTR2006-006543-31-ATux Biosciences GmbH325
进行中（未招募）
1 期
A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study with an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis.Subjects with active sight-threatening, non-infectious intermediate-, anterior and intermediate-, posterior- or pan-uveitis.MedDRA version: 8.1 Level: LLT Classification code 10046851 Term: UveitisEUCTR2006-006543-31-GBux Biosciences GmbH335
进行中（未招募）
不适用
A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Centre, Dose-Ranging Study with an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Clinically Quiescent Sight Threatening, Non-Infectious Intermediate-, Anterior and Intermediate-, Posterior, or Pan-Uveitis.Subjects with clinically quiescent sight-threatening, non-infectious intermediate-, anterior and intermediate-, posterior- or pan-uveitis requiring systemic immune suppression.MedDRA version: 8.1Level: LLTClassification code 10046851Term: UveitisEUCTR2006-006544-66-DEux Biosciences GmbH350
进行中（未招募）
1 期
A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis.EUCTR2006-006543-31-FRux Biosciences GmbH335
进行中（未招募）
不适用
A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study with an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious, Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis.Subjects with active sight-threatening, non-infectious intermediate-, anterior and intermediate-, posterior- or pan-uveitis.MedDRA version: 8.1Level: LLTClassification code 10046851Term: UveitisEUCTR2006-006543-31-DEux Biosciences GmbH325